Systemic inflammation in chronic obstructive pulmonary disease: A population-based study

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Garcia Rio, Francisco ^a   Miravitlles, Marc ^b   Soriano, Joan B ^c   Muñoz, Luis ^d   Duran Tauleria, Enric ^e   Sánchez, Guadalupe ^f   Sobradillo, Víctor ^g   Ancochea, Julio ^h  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^f GLAXOSMITHKLINE   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; NITRATE; NITRITE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; SPIROMETRY; TOBACCO; WALKING; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; EXERCISE TEST; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; SPAIN; UPREGULATION; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPAIN; UP-REGULATION; VITAL CAPACITY;

EID: 77956704227     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-63     Document Type: Article

References (39)

1. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1791-1797.
2. Maltais F, Simard AA, Simard C, Jobin J, Desgagnés P, LeBlanc P. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996, 153:288-293.
3. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007, 4:522-525. 10.1513/pats.200701-004FM, 17878464.
4. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007, 370:797-799. 10.1016/S0140-6736(07)61383-X, 17765529.
5. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: Data from the third national health and nutrition examination. Am J Med 2003, 114:758-762. 10.1016/S0002-9343(03)00185-2, 12829203.
6. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1008-1011.
7. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996, 154:1055-1060.
8. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580. 10.1136/thx.2003.019588, 1747070, 15223864.
9. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodríguez-Roisin R, van Weel C, Zielinski J, . Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545, Global Initiative for Chronic Obstructive Lung Disease.
10. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Therap 2006, 19:189-199.
11. Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, Neukirch F, Zureik M. Change in C-reactive protein levels and FEV1 decline: A longitudinal population-based study. Respir Med 2006, 100:2112-2120. 10.1016/j.rmed.2006.03.027, 16650972.
12. Senn O, Russi EW, Schindler C, Imboden M, von Exkardstein A, Brändli O, Zemp E, Ackermann-Liebrich U, Berger W, Rochat T, Luisetti M, Probst-Hensch NM. Circulating alpha 1-antitrypsin in the general population: Determinants and association with lung function. Respir Res 2008, 9:35. 10.1186/1465-9921-9-35, 2413219, 18439253.
13. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, Olafsson I, Benediktsdottir B, Janson C, Buist AS, Gislason T. Chronic airflow obstruction and markers of systemic inflammation: Results from the BOLD study in Iceland. Respir Med 2009, 103:1548-1553. 10.1016/j.rmed.2009.04.005, 19427181.
14. van Durme YMTA, Verhamme KMC, Aarnoudse AJLHJ, Van Pottelberge GR, Hofman A, Witteman JCM, Joos GF, Brusselle GG, Stricker BHC. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:375-382. 10.1164/rccm.200810-1540OC, 19096002.
15. Ancochea J, Badiola C, Duran-Tauleria E, Garcia-Rio F, Miravitlles M, Muñoz L, Sobradillo V, Soriano JB. The EPI-SCAN survey to assess the prevalence of chronic obstructive pulmonary disease in Spanish 40-to-80-year-olds: protocol summary. Arch Bronconeumol 2009, 45:41-47. 10.1016/j.arbres.2008.06.001, 19186298.
16. Miravitlles M, Soriano JB, Garcia-Rio F, Muñoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J. Prevalence of COPD in Spain and impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009, 64:863-868. 10.1136/thx.2009.115725, 19553233.
17. Celli BR, Cote CG, Marin JM, Casanova C, Montes D, Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012. 10.1056/NEJMoa021322, 14999112.
18. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Grinten CP, Gustafsson P, Jensen R, Jonson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardization of spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882.
19. Roca J, Sanchis J, Agustí-Vidal A, Segarra F, Navajas D, Rodríguez-Roisin R, Casan P, Sans S. Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir 1986, 22:217-224.
20. ATS Statement Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-116. ATS Statement.
21. Snijders T, Bosker R. Multilevel analysis: an introduction to basic and advanced multilevel modeling 1999, London: Sage.
22. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005, 579:2035-2039. 10.1016/j.febslet.2005.02.055, 15811314.
23. Ben-Zaken Cohen S, Paré PD, Man SFP, Sin DD. The growing burden of chronic obstructive pulmonary disease and lung cancer in women. Examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med 2007, 176:113-120. 10.1164/rccm.200611-1655PP, 17413125.
24. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002, 166:1218-1224. 10.1164/rccm.2202023, 12403691.
25. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF, Lipinska I, O'Connor GT, Benjamin EJ. Systemic Inflammation and COPD. The Framingham Heart Study. Chest 2008, 133:19-25. 10.1378/chest.07-0058, 17908709.
26. Franssen FM, O'Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. Thorax 2008, 63:1110-1117. 10.1136/thx.2007.086827, 19020276.
27. De Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006, 27:902-907.
28. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Gan WQ, Rousseau R. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:1207-1214. 10.1164/rccm.200709-1356OC, 18310480.
29. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000, 343:269-280. 10.1056/NEJM200007273430407, 10911010.
30. Vliet A, Eiserich JP, Shigenaga MK, Cross CE. Reactive nitrogen species and tyrosine nitration in the respiratory tract. Am J Respir Crit Care Med 1999, 160:1-9.
31. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519. 10.1161/01.CIR.0000056767.69054.B3, 12654609.
32. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003, 22:809-814. 10.1183/09031936.03.00031403, 14621089.
33. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255. 10.1164/rccm.200605-713OC, 17053205.
34. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007, 62:515-520. 10.1136/thx.2006.066969, 2117221, 17251312.
35. Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61:17-22. 10.1136/thx.2005.041996, 2080712, 16055618.
36. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006, 61:23-28. 10.1136/thx.2005.042200, 2080714, 16143583.
37. Mannino D. Defining chronic obstructive pulmonary disease... and the elephant in the room. Eur Respir J 2007, 30:189-19. 10.1183/09031936.00058707, 17666553.
38. Pellegrino R, Brusasco V, Viegi G, Crapo RO, Burgos F, Casaburie R, Coates A, Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyreee N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Definition of COPD: based on evidence or opinion?. Eur Respir J 2008, 31:681-69. 10.1183/09031936.00154307, 18310402.
39. Mannino DM, Buist AS, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. Thorax 2007, 62:237-241. 10.1136/thx.2006.068379, 2117148, 17090573.